Medidata launches myMedidata Registries make clinical trials better for patients

The service extends the myMedidata patient portal to address a critical need in clinical development by engaging patients pre- and post-trial.

myMedidata Registries

Medidata launched myMedidata Registries, a new technology that expands and strengthens the myMedidata patient portal to engage patients before and after a clinical trial. This empowers patients to learn more about clinical trial opportunities and provides an experience that allows for active participation throughout their clinical trial journey.

With increasing interest and adoption of decentralized clinical trials, myMedidata Registries gives patients continuous support in and out of a trial with access to one portal for all of their research needs – providing an everlasting engagement on one portal for life.

Why does it matter?

Built directly on the Medidata Clinical Cloud, myMedidata Registries provides education, pre-screening, patient data collection, and opportunities for video visits before a patient travels to a site or is enrolled into a study. Clinical trial sponsors and CROs using myMedidata Registries have a direct, secure connection with trial participants via notifications and alerts, allowing them to optimize trial participation, and increase product and trial awareness.

The service — first introduced in the US and with other countries to follow — provides sponsors with one, unified ecosystem for patient identification, study execution and end-of-study patient communications, including patient data return. Once a new therapeutic, vaccine or medical device is on the market, myMedidata Registries allows sponsors and CROs to continue to engage with participants when long term follow up (LTFU) and safety monitoring is required. Regulators require LTFU for thousands of studies, with human gene therapies needing 15 to 30 years or more. Additionally, myMedidata Registries can be used to bridge patients moving from Phase 2/3 to Phase 4 clinical trials.

The service was designed for patients by patients, in partnership with Medidata’s Patient Insights team. Medidata’s team of dedicated patient advocates uses the Patient Centricity by Design (PCbD) process that infuses the patient perspective into the software development life cycle to create technical solutions that improve the overall patient experience in clinical research interactions. The PCbD initiative was named the first-place winner at the 2021 SCOPE Participant Engagement Awards.

On the record

“The time for myMedidata Registries is now,” said Anne Marie Mercurio, a distinguished patient advocate and caregiver, and a member of Medidata’s Patient Insights team. “The patient community needs a quick, easy, secure way to get engaged with clinical research. My message is: Don’t miss out – the more who join, the faster we can get the scientific evidence to better understand and treat diseases.”

“myMedidata Registries is designed to transform patients’ clinical trial experiences from being a transactional and impersonal process to a seamless and engaging one that deepens relationships between participants, sponsors, and trial sites,” said Kelly McKee, Vice President, Patient Registries and Recruitment at Medidata. “This redefines Medidata’s end-to-end technology solutions and represents a major advance for the life science industry, providing patients with a new option to pursue care.” See how the registry works by clicking here.

The context

Issues surrounding patient awareness of and access to clinical trials have been roadblocks to participation for many years. According to the Center for Information and Study on Clinical Research Participation (CISCRP), only 25% of individuals reported being “very confident” in their ability to find a clinical research study. Furthermore, 98% of individuals surveyed were willing to participate in another study, yet many reported they never heard back from anyone after the study was completed, be it clinical trial results, patient data return, a thank you note, or an invitation to a new study. These individuals are never engaged and the traditional recruitment cycle starts anew with each upcoming trial.